Short description
Onxeo is a biotechnology company that develops drugs for oncology.
Description
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma.
Onxeo is headquartered in Paris, France.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Paris, Ile-de-France, France, Europe
Founded on
January 1, 1997
Exited on
December 16, 2005
Went public on
December 16, 2005
Stock symbol
ONXEO
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Noaccess, Noaccess, No Way, Noaccessforu
Sign in for full access
Founders
Gilles Avenard